Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, but its treatment is challenging, which may be due to lack of focus. Recent years have seen considerable developments in biotargeted therapies targeting two important pathophysiologic mechanisms for treatin...
Format: | Article |
---|---|
Language: | zho |
Published: |
Chinese General Practice Publishing House Co., Ltd
2022-02-01
|
Series: | Zhongguo quanke yixue |
Subjects: | |
Online Access: | https://www.chinagp.net/fileup/1007-9572/PDF/1643096232815-1974372297.pdf |
Similar Items
-
Glucocorticoids: A review of its adverse effects including bone loss
by: Amit Dua, et al.
Published: (2019-01-01) -
Effects of E’Jiao on Skeletal Mineralisation, Osteocyte and WNT Signalling Inhibitors in Ovariectomised Rats
by: Kok-Yong Chin, et al.
Published: (2023-02-01) -
Sclerostin antibodies as novel anabolic therapy for osteoporosis
by: Elizaveta O. Mamedova, et al.
Published: (2019-04-01) -
Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Chuanjian Yuan, et al.
Published: (2023-06-01) -
Glucocorticoid-Induced Osteoporosis: The Potential Role of Romosozumab
by: Jacqueline So, et al.
Published: (2020-12-01)